Interaction of plasma proteins with cholinergic system during inflammation

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Literature data analysis revealed that plasma proteins have polyfunctional action. The common property of IgG and CRP is their ability to bind to Fcy-receptors of the target cells (endotheliocytes, monocytes, macrophages, neutrophiles, lymphocytes). Moreover IgG and albumin bind to endothelial cell neonatal Fc-receptors which protect these proteins from catabolic degradation. Proteins are able to interact with each other (IgG, CRP), with cationic proteins (CRP), with acetylcholine (albumin, CRP); to possess own nuclease, peptidase, amylolytic enzyme activity and bactericidal action (IgG); to have redox properties, transport functions (albumin), pro- and antiinflammatory properties. Antiinflammatory effects of albumin are connected with its influence on cellular membrane anisotropic properties and inflammatory mediators neutralization; IgG eliminates antigens, competes with autoantibodies and allergenspecific antibodies for the binding to Fcy-receptors, has self catalytic activity and ability to enhance the antianaphylactic effects of cholinergic antagonists; CRP modulates immune cells functions and binds with decay products of disintegrated cells. Alteration in proteins production leads to disturbances in cholinergic regulation of vascular tone and several metabolic reactions and so intensifies the proinflammatory response. These data extend our notion about functions of plasma proteins and may have implications in combined application of proteins with cholinergic antagonists during inflammation.

About the authors

N. S. Sapronov

Research Institute of Experimental Medicine of the RAMS

Author for correspondence.
Email: shabanov@mail.rcom.ru

Член-корреспондент РАМН

Russian Federation, St. Petersburg

G. I. Nezhinskaya

Research Institute of Experimental Medicine of the RAMS

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg

A. L. Vladykin

Research Institute of Experimental Medicine of the RAMS

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg

References

  1. Гущин И. С. Взаимодействие клеток иммунного и эффекторного звеньев аллергического ответа и возможные пути его фармакологического контроля // Иммунология. 1994. №4. С. 8-9.
  2. Назаров П. Г., Крылова И. Б., Нежинская Г. И. и др. С-реактивный белок: фактор воспаления, связывающий и инактивирующий ацетилхолин // Цитокины и воспаление. 2006. Т. 5. № 4. С. 32-35.
  3. Назаров П. Г., Нежинская Г. И., Бутюгов А. А. и др. Петраксины и нейромедиаторы // Мед. иммунол. 2006. Т. 8. № 2-3. С. 161.
  4. Нежинская Г. И., Назаров П. Г., Евдокимова Н. Р. и др. Холинергическая регуляция анафилактического шока: влияние С-реактивного белка // Цитокины и воспаление. 2004. Т. 3. № 1. С. 44-48.
  5. Нежинская Г. И., Лосев Н. А., Назаров П. Г. и др. Влияние ацетилхолина и С-реактивного белка на регуляцию анафилактического шока у морских свинок // Экспер. и клин. фармакол. 2005. Т. 68. № 4. C. 49-52.
  6. Нежинская Г. И., Лосев Н. А., Сапронов Н. С. Холинергическая система лимфоцитов // Экспер. и клин. фармакол. 2006. Т. 69. № 6. С. 63–67.
  7. Нежинская Г. И., Владыкин А. Л., Сапронов Н. С. Фармакологический анализ неканонических лигандов никотиновых холинорецепторов // Психофармакология и биологическая наркология. 2007. Т. 7. Вып. 2. С. 1526-1530.
  8. Харкевич Д. А. Фармакология. М.: ГЭОТАР-Медицина, 2003.
  9. Akilesh S., Petkova S., Sproule T. J. et al. The МНС class I-like Fc receptor promotes humorally mediated autoimmune disease // J. Clin. Invest. 2004. Vol. 113. № 9. Р. 1328-1333.
  10. Alvarez B., Ferrer-Sueta G., Freeman B. A. et al. Kinetics of peroxynitrite reactions with amino acids and human serum albumin // J. Biol. Chem. 1999. Vol. 274. № 2. Р. 842-848.
  11. Anderson C. L., Shen L., Eicher D. M. et al. Phagocytosis mediated by three distinct Fc gamma receptor classes on human leukocytes // J. Exp. Med. 1990. Vol. 171. № 4. Р. 1333-1345.
  12. Anegon I., Cuturi M. C., Trinchieri G. et al. Interaction of Fc receptors (CD16) with ligands induces transcription of IL-2 receptor (CD25) and lymphokine genes and expression of their products in human NK cells // J. Exp. Med. 1988. Vol. 167. № 2. Р. 452-472.
  13. Beck R., Bertolino S., Abbot S. E. et al. Modulation of arachidonic acid release and membrane fluidity by albumin in vascular smooth muscle and endothelial cells // Circulation Research. 1998. Vol. 83. № 9. P. 923-931.
  14. Birdsall N. J., Chan S. C., Eveleigh P. et al. The modes of binding of ligands to cardiac muscarinic receptors // Trends Pharmacol. Sci. 1989. Suppl. P. 31-34.
  15. Black S., Agrawal A., Samols D. The phosphocholine and the polycation-binding sites on rabbit C-reactive protein are structurally and functionally distinct // Mol. Immunol. 2003. Vol. 39. № 16. Р. 1045-1054.
  16. Black S., Kushner I., Samols D. C-reactive protein // J. Biol. Chem. 2004. Vol. 279. Р. 48487-48490.
  17. Camacho M., Balagangadhar R. T., Torbati D. et al. Pulmonary and extrapulmonary effects of increased colloid osmotic pressure during endotoxemia in rats // Chest. 2001. Vol. 120. № 5. Р. 1655-1662.
  18. Cantin A. M., Paquette B., Richter M. et al. Albuminmediated regulation of cellular glutathione and nuclear factor kappa B activation // Am. J. Respir. Crit. Care Med. 2000. Vol. 162. P. 1539-1546.
  19. Caulfield M. P., Birdsall N. J. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors // Pharmacol. Rev. 1998. Vol. 50. № 2. Р. 279-290.
  20. Chaudhury C., Mehnaz S., Robinson J. M. et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan // J. Exp. Med. 2003. Vol. 197. № 3. Р. 315-322.
  21. Chi M., Tridandapani A., Zhong W. et al. C-reactive protein induces signaling through FcyRIIa on HL60 granulocytes // J. Immunol. 2002. Vol. 168. № 3. P. 1413-1418.
  22. Clapp B. R., Hirschfield G. M., Storry C. et al. Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability // Circulation. 2005. Vol. 111. № 12. Р. 1530- 1536.
  23. Cohen M. D., Sisco M., Li Y. et al. Ozone-induced modulation of cell-mediated immune responses in the lungs // Toxicol. Appl. Pharmacol. 2001. Vol. 171. № 2. P. 71-84.
  24. Crockett-Torabi E., Fantone J. C. Soluble and insoluble immune complexes activate human neutrophil NADPH oxidase by distinct Fcy receptor-specific mechanisms // J. Immunol. 1990. Vol. 145. № 9. Р. 3026-3032.
  25. Crow A. R., Song S., Freedman J. et al. IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity // Blood. 2003. Vol. 102. P. 558-560.
  26. Crowell R. E., Du Clos T. W., Montoya G. et al. C-reactive protein receptors on the human monocytic cell line U-937: evidence for additional binding to FcyRI // J. Immunol. 1991. Vol. 147. № 10. Р. 3445-3451.
  27. Dall'Acqua W. F., Kiener P. A., Wu H. Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn) // J. Biol. Chemistry. 2006. Vol. 281. № 33. P. 23514-23524.
  28. Dougherty T. J., Gewurz H., Siegel J. N. Preferential binding and aggregation of rabbit C-reactive protein with arginine-rich proteins // Mol. Immunol. 1991. Vol. 28. № 10. Р. 1113-1120.
  29. Du Clos T. W., Zlock L. T., Marnell L. Definition of a C-reactive protein binding determinant on histones // J. Biol. Chem. 1991. Vol. 266. № 4. Р. 2167–2171.
  30. Du Clos T. W., Zlock L. T., Hicks P. S. et al. Decreased autoantibody levels and enhanced survival of (NZB x NZW)F1 mice treated with C-reactive protein // Clin. Immunol. Immunopathol. 1994. Vol. 70. № 1. P. 22-27.
  31. Du Clos T. W. The interaction of C-reactive protein and serum amyloid P component with nuclear antigens // Mol. Biol. Rep. 1996. Vol. 23. P. 253–260.
  32. Du Clos T. W. Function of C-reactive protein // Ann. Med. 2000. Vol. 32. № 4. Р. 274-278.
  33. Fanger M. W., Graziano R. F., Shen L. et al. FcyR in cytotoxicity exerted by mononuclear cells // Chem. Immunol. 1989. Vol. 47. Р. 214-253.
  34. Fichtlscherer S., Rosenberger G., Walter D. H. et al. Elevated C-reactive protein lévels and impaired endothelial vasoreactivity in patients with coronary artery disease // Circulation. 2000. Vol. 102. № 9. P. 1000-1006.
  35. Fraser C. M., Wang C. D., Robinson D. A. et al. Site-directed mutagenesis of ml muscarinic acetylcholine receptors: conserved aspartic acids play important roles in receptor function // Mol. Pharmacol. 1989. Vol. 36. № 6. Р. 840-847.
  36. Friboulet A., Avalle B., Debat H. et al. A possible role of catalytic antibodies in metabolism // Immunol. Today. 1999. Vol. 20. № 10. Р. 474-475.
  37. Fryer A. D., Maclagan J. Muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea-pig // Br. J. Pharmacol. 1984. Vol. 83. № 4. P. 973-978.
  38. Gerber J. S., Mosser D. M. Reversing lipopolysaccharide toxicity by ligating the macrophage Fcy receptors // J. Immunol. 2001. Vol. 166. № 11. Р. 6861-6868.
  39. Hansen U. K., Chuang V., Otagiri M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin // Biological and Pharmaceutical Bulletin. 2002. Vol. 25. № 6. Р. 695-704.
  40. Hu J., Wang S. Z., Forray C. et al. Complex allosteric modulation of cardiac muscarinic receptors by protamine: a potential model for putative endogenous ligands // Mol. Pharmacol. 1992. Vol. 42. № 2. Р. 311-324.
  41. Hulett M. D., Hogarth P. M. Molecular basis of Fc receptor function // Adv. Immunol. 1994. Vol. 57. P. 1-127.
  42. Isashi Y., Yamashita T., Nagasawa S. et al. The mechanism by which proteolysis enhances the ligandbinding activity of guinea pig type II Fc receptor for IgG (FcyRIIB) // J. Biochem. 1998. Vol. 123. № 5. P. 959-967.
  43. Kaneko Y., Nimmerjahn F., Madaio M. P. et al. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors // J. Exp. Med. 2006. Vol. 203. № 3. Р. 789-797.
  44. Kawashima K., Fujii T. The lymphocytic cholinergic system and its contribution to the regulation of immune activity //Life Sci. 2003. Vol. 74. № 6. Р. 675–696.
  45. Kim J., Bronson C. L., Hayton W. L. et al. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces // Am. J. Physiol. Gastrointest. Liver Physiol. 2006. Vol. 290. № 2. P. G352-G360.
  46. Kim J., Haytonb W. L., Robinson J. M. et al. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model // Clin. Immunol. 2007. Vol. 122. № 2. Р. 146-155.
  47. Kouoh F., Gressier B., Luyckx M. et al. Antioxidant properties of albumin: Effect on oxidative metabolism of human neutrophil granulocytes // Farmaco. 1999. Vol. 54. № 10. Р. 695-699.
  48. Lacroix-Desmazes S., Bayry J., Kaveri S. V. et al. High levels of catalytic antibodies correlate with favorable outcome in sepsis // Proc. Natl. Acad. Sci. USA. 2005. Vol. 102. №. 11. Р. 4109-4113.
  49. Lacroix-Desmazes S., Wootla B., Delignat S. et al. Pathophysiology of catalytic antibodies // Immunol. Lett. 2006. Vol. 103. № 1. Р. 3-7.
  50. Lang J. D. Jr., Figueroa M., Chumley P. et al. Albumin and hydroxyethyl starch modulate oxidative inflammatory injury to vascular endothelium // Anesthesiology. 2004. Vol. 100. № 1. Р. 51-58.
  51. Lawand N. B., Lu Y., Westlund K. N. Nicotinic cholinergic receptors: potential targets for inflammatory pain relief // Pain. 1999. Vol. 80. Р. 291–299.
  52. Lee N. H., El-Fakahany E. E. Allosteric antagonists of the muscarinic acetylcholine receptor // Biochem. Pharmacol. 1991. Vol. 42. № 2. Р. 199-205.
  53. Lee N. H., El-Fakahany E. E. Allosteric interactions at the ml, m2 and m3 muscarinic receptor subtypes // J. Pharmacol. Exp. Ther. 1991. Vol. 256. № 2. P. 468-479
  54. Lee R. T., Takagahara I., Lee Y. С. Mapping the binding areas of human C-reactive protein for phosphorylcholine and polycationic compounds. Relationship between the two types of binding sites // J. Biol. Chem. 2002. Vol. 277. № 1. Р. 225-232.
  55. Lee K. Y., Lee J. S. Immunoglobulin G has a role for systemic protein modulation in vivo: a new concept of protein homeostasis // Med. Hypotheses. 2006. Vol. 67. № 4. Р. 848-855.
  56. Lewis C. A., Martin G. S. Understanding and managing fluid balance in patients with acute lung injury // Curr. Opin. Crit. Care. 2004. Vol. 10. № 1. Р. 13-17.
  57. Liederer B. M., Borchardt R. Enzymes involved in the bioconversion of ester-based prodrugs // J. Pharmaceutical Sci. 2006. Vol. 95. № 6. Р. 1177–1195.
  58. Liu L., Yan Y., Zeng M. et al. Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock // Cell. 2004. Vol. 116. № 4. P. 617-628.
  59. Lum H., Siflinger-Birnboim A., Blumenstock F. et al. Serum albumin decreases transendothelial permeability to macromolecules // Microvasc. Res. 1991. Vol. 42. № 1. Р. 91-102.
  60. Martin G. S., Mangialardi R. J., Wheeler A. P. et al. A1- bumin and furosemide therapy in hypoproteinemic patients with acute lung injury // Crit. Care Med. 2002. Vol. 30. № 10. Р. 2175-2182.
  61. Meziani F., Kremer H., Tesse A. et al. Human serum albumin improves arterial dysfunction during early resuscitation in mouse endotoxic model via reduced oxidative and nitrosative stresses // Am. J. Pathol. 2007. Vol. 171. № 6. Р. 1753–1761.
  62. Mineo C., Gormley A. K., Yuhanna I. S. et al. FcyRIIb mediates C-reactive protein inhibition of endothelial NO synthase // Circ. Res. 2005. Vol. 97. № 11. P. 1124-1131.
  63. Mold C., Nakayama S., Holzer T. J. et al. C-reactive protein is protective against Streptococcus pneumoniae infection in mice // J. Exp. Med. 1981. Vol. 154. № 5. Р. 1703-1708.
  64. Motie M., Brockmeier S., Potempa L. A. Binding of model soluble immune complexes to modified C-reactive protein // J. Immunol. 1996. Vol. 156. № 11. P. 4435-4441.
  65. Nathan C., Xie Q. W., Halbwachs-Mecarelli L. et al. Albumin inhibits neutrophil spreading and hydrogen peroxide release by blocking the shedding of CD43 (sialophorin, leukosialin) // J. Cell. Biol. 1993. Vol. 122. № 1. Р. 243-256.
  66. Nevinsky G. A., Buneva V. N. Human catalytic RNAand DNA-hydrolyzing antibodies // J. Immunol. Methods. 2002. Vol. 269. P. 235-249.
  67. Nezhinskaya G. I., Vladykin A. L., Sapronov N. S. Cholinergic modulation of anaphylactic shock: plasma proteins influence // Life Sci. 2007. Vol. 80. Р. 2342–2346.
  68. Nieva J., Wentworth P. The antibody-catalyzed water oxidation pathway-a new chemical arm to immune defense? // Trends Biochem. Sci. 2004. Vol. 29. № 5. P. 274-285.
  69. Nimmerjahn F., Ravetch J. V. Fcy receptors: old friends and new family members // Immunity. 2006. Vol. 24. № 1. Р. 19-28.
  70. Pepys M. B., Hirschfield G. M. C-reactive protein: a critical update // J. Clin. Invest. 2003. Vol. 111. № 12. P. 1805-1812.
  71. Peters T. Jr. Serum albumin: recent progress in the understanding of its structure and biosynthesis // Clin. Chem. 1977. Vol. 23. № 1. Р. 5-12.
  72. Potempa L. A., Gewurz H. Influence of heparin on interactions between C-reactive protein and polycations // Mol. Immunol. 1983. Vol. 20. № 5. P. 501-509.
  73. Prasad A., Zhu J., Halcox J. P. et al. Predisposition to atherosclerosis by infections: role of endothelial dysfunction // Circulation. 2002. Vol. 106. № 2. Р. 184-190.
  74. Quinlan G. L., Margarson M. P., Mumby S. et al. Administration of albumin to patients with sepsis syndrome: a possible beneficial role in plasma thiol repletion // Clin. Sci. 1998. Vol. 95. № 4. Р. 459-465.
  75. Quinlan G. J., Mumby S., Martin G. S. et al. Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury // Crit. Care Med. 2004. Vol. 32. № 3. Р. 755-759.
  76. Quinlan G. J., Martin G. S., Evans T. W. Albumin: biochemical properties and therapeutic potential // Hepatology. 2005. Vol. 41. № 6. Р. 1211–1219.
  77. Radi R., Bush K. M., Cosgrove T. P. et al. Reaction of xanthineoxidase derived oxidants with lipid and protein of human plasma // Arch. Biochem. Biophys. 1991. Vol. 286. № 1. Р. 117–125.
  78. Rafikova O., Rafikov R., Nudler E. Catalysis of S-nitrosothiol formation by serum albumin: the mechanism and implication in vascular control // Proc. Natl. Acad. Sci. 2002. Vol. 99. № 9. Р. 5913-5918.
  79. Rhee P., Wang D., Ruff P. et al. Human neutrophil activation and increased adhesion by various resuscitation fluids // Crit. Care Med. 2000. Vol. 28. № 1. Р. 74-78.
  80. Roman M. J., Shanker B. A., Davis A. et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus // N. Engl. J. Med. 2003. Vol. 349. Р. 2399–2406.
  81. Ruot B., Becherea F., Bayle G. et al. The response of liver albumin synthesis to infection in rats varies with the phase of the inflammatory process // Clin. Sci. (Lond.). 2002. Vol. 102. № 1. Р. 107-114.
  82. Saeed R. W., Varma S., Peng-Nemeroff T. et al. Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation // J. Exp. Med. 2005. Vol. 201. № 7. Р. 1113-1123.
  83. Samuelsson A., Towers T. L., Ravetch J. V. Anti-inflammatory activity ofIVIG mediated through the inhibitory Fc receptor // Science. 2001. Vol. 291. P. 484-486.
  84. Scallon B. J., Tam S. H., McCarthy S. G. et al. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality // Mol. Immunol. 2007. Vol. 44. № 7. Р. 1524-1534.
  85. Simard J. R., Zunszain P. A., Hamilton J. A. et al. Location of high and low affinity fatty acid binding sites on human serum albumin revealed by NMR drug-competition analysis // J. Mol. Biol. 2006. Vol. 361. № 2. P. 336-351.
  86. Sinisalo J., Paronen J., Mattila K. J. et al. Relation of inflammation to vascular function in patients with coronary heart disease // Atherosclerosis. 2000. Vol. 149. № 2. Р. 403-411.
  87. Siragam V., Crow A.R., Brinc D. et al. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells // Nat. Med. 2006. Vol. 12. № 6. Р. 688-692.
  88. Stein M. P., Mold C., Du Clos T. W. C-reactive protein binding to murine leukocytes requires Fcy receptors // J. Immunol. 2000. Vol. 164. № 3. Р. 1514–1520.
  89. Sutterwala F. S., Noel G. J., Salgame P. et al. Reversal of proinflammatory responses by ligating the macrophage Fcy receptor type I // J. Exp. Med. 1998. Vol. 188. № 1. Р. 217-222.
  90. Szalai A. J., Briles D. E., Volanakis J. E. Role of complement in C-reactive protein-mediated protection of mice from Streptococcus pneumoniae // Infect. Immunol. 1996. Vol. 64. № 11. Р. 4850-4853.
  91. Szalai A. J., VanCott J. L., McGhee J. R. Human Creactive protein is protective against fatal Salmonella enterica serovar typhimurium infection in transgenic mice // Infect. Immunol. 2000. Vol. 68. № 10. P. 5652-5656.
  92. Toda N., Okamura T. The pharmacology of nitric oxide in the peripheral nervous system of blood vessels // Pharmacol. Rev. 2003. Vol. 55. № 2. Р. 271–324.
  93. Toubi E., Etzioni A. Intravenous immunoglobulin in immunodeficiency states: state of the art // Clin. Rev. Allergy Immunol. 2005. Vol. 29. № 3. Р. 167–172.
  94. Tsiotou A. G., Sakorafas G. H., Anagnostopoulos G. et al. Septic shock: current pathogenetic concepts from a clinical perspective // Med. Sci. Monit. 2005. Vol. 11. № 3. P. RA76-85.
  95. Vaccaro C., Zhou J., Ober R. J. et al. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels // Nat. Biotechnol. 2005. Vol. 23. № 10. Р. 1283–1288.
  96. Vaudo G., Marchesi S., Gerli R. et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity // Ann. Rheum. Dis. 2004. Vol. 63. № 1. Р. 31–35.
  97. Venugopal S. K., Devaraj S., Yuhanna I. et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells // Circulation. 2002. Vol. 106. № 12. Р. 1439–1441.
  98. Verma S., Li S. H., Badiwala M. V. et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein // Circulation. 2002. Vol. 105. P. 1890-1896.
  99. Verma S., Wang C. H., Li S. H. et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis // Circulation. 2002. Vol. 106. P. 913-919.
  100. Walker B. A., Hagenlocker B. E., Stubbs Jr. E. B. et al. Signal transduction events and FcyR engagement in human neutrophils stimulated with immune complexes // J. Immunol. 1991. Vol. 146. № 2. Р. 735-741.
  101. Wentworth A., Jones L., Wentworth P. et al. Antibodies have the intrinsic capacity to destroy antigens // Proc. Natl. Acad. Sci. USA. 2000. Vol. 97. P. 10930- 10932.
  102. Wentworth P. Jr., McDunn J. E., Wentworth A. D. et al. Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation // Science. 2002. Vol. 298. Р. 2195-2199.
  103. Wessler I., Kilbinger H., Bittinger F. et al. The biological role of non-neuronal acetylcholine in plants and humans // Jpn. J. Pharm. 2001. Vol. 85. № 1. P. 2-10.
  104. Wessler I., Reinheimer T., Kilbinger H. et al. Increased acetylcholine levels in skin biopsy of patients with atopic dermatitis // Life Sci. 2003. Vol. 72. P. 2055-2061.
  105. Whisler R. L., Newhouse Y. G., Mortensen R. F. Creactive protein- (CRP) mediated modulation of human B cell colony development // J. Immunol. 1983. Vol. 130. № 1. Р. 248-253.
  106. Xia D., Samols D. Transgenic mice expressing rabbit C-reactive protein are resistant to endotoxemia // Proc. Natl. Acad. Sci. USA. 1997. Vol. 94. P. 2575-2580.
  107. Yan Z. Q., Hansson G. K. Innate immunity, macrophage activation, and atherosclerosis // Immunol. Rev. 2007. Vol. 219. Р. 187–203.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2008 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.